StimCell Enegetics

StimCell Enegetics FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of StimCell Enegetics (STME) as of Oct 21, 2026 is 34.85 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 25.00 % — a change of 39.39% (higher).

FCF Conversion

34.85 %

YoY

39.39%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of StimCell Enegetics is 2026 34.85 % . FCF Conversion Rate (FCF/EBITDA) of StimCell Enegetics was 2025 25.00 % . It decreases by 39.39% higher compared to the previous year.

The StimCell Enegetics FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
33.54 USD
Jan 1, 2020
84.96 USD
Jan 1, 2021
61.70 USD
Jan 1, 2022
64.61 USD
Jan 1, 2023
54.99 USD
Jan 1, 2024
102.39 USD
Jan 1, 2025
25.00 USD
Jan 1, 2026
34.85 USD
The StimCell Enegetics FCF Conversion history
YEARFCF ConversionYoY
34.85 %+39.39%
25.00 %-75.58%
102.39 %+86.22%
54.99 %-14.90%
64.61 %+4.72%
61.70 %-27.37%
84.96 %+153.31%
33.54 %+15.43%
29.06 %-58.00%
69.17 %+131.08%
29.94 %-10.34%
33.39 %-83.54%
202.82 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

StimCell Enegetics Stock analysis

What does StimCell Enegetics do? Cell MedX Corp. makes money through its subsidiary Avyonce Cosmedics Inc., which resells spa technology and equipment to the beauty and wellness industry. Avyonce also markets eBalance Technology, used for micro current treatments targeting diabetes and related ailments, and conducts observational studies with this technology. The company provides continuing education for estheticians and healthcare professionals in medical aesthetics. Avyonce Cosmedics Inc. serves the beauty and wellness industry, focusing on professionals who use spa technology and equipment. The firm develops a family of devices based on eBalance Technology, which is applied in treatments for diabetes and related conditions. This technology is central to Avyonce's product offerings and educational services. Cell MedX Corp. operates as a development stage company with no full-time employees, relying on its subsidiary Avyonce to drive revenue. The company's business model centers on the commercialization of eBalance Technology through product sales, educational programs, and observational studies in the medical aesthetics sector. StimCell Enegetics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about StimCell Enegetics stock

FCF Conversion Rate (FCF/EBITDA) of StimCell Enegetics is 34.85 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of StimCell Enegetics changed from 25.00 % to 34.85 %, representing a 39.39% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) StimCell Enegetics since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s StimCell Enegetics with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — StimCell Enegetics

All Key Metrics — StimCell Enegetics